$90 million new gift to university from Penny and Philip H. Knight follows their earlier commitment of $75 million to school

Penny and Philip H. Knight have once again deepened their imprint on the future of biomedical science with a $90 million gift to Stanford University, extending the Knight Initiative for Brain Resilience at the Wu Tsai Neurosciences Institute.

This contribution builds on their $75 million founding commitment in 2022 and reflects a philanthropic focus on high-risk, high-reward scientific inquiry—especially in areas where traditional funding has struggled to make meaningful progress.

At Stanford, the expanded initiative is designed to reframe one of the most stubborn challenges in modern medicine: the biology of aging and the persistence of neurodegenerative disease.

Rather than concentrating solely on the pathology of conditions such as Alzheimer’s and Parkinson’s, the Knight Initiative has distinguished itself by asking a more unconventional question—why do some individuals retain cognitive vitality deep into old age?

The additional funding will accelerate efforts to map the molecular and cellular foundations of that resilience, combining large-scale biological data collection with artificial intelligence and experimental modeling to identify pathways that might preserve brain function across the lifespan.

The gift reflects a broader evolution in the Knights’ philanthropy, which over the past decade has become increasingly aligned with transformative scientific and medical research. Phil Knight, the co-founder of Nike, has long been one of the most consequential donors in American higher education and health sciences, with cumulative giving in the billions.

Much of that philanthropy has been directed toward his alma mater, the University of Oregon, where his contributions have reshaped both academic and athletic infrastructure, including landmark investments in cancer research through the Knight Cancer Institute.

There, as at Stanford, Knight’s giving has often been structured to catalyze additional funding, most notably through challenge grants that have unlocked hundreds of millions in matching support.

Together, Penny and Phil Knight have demonstrated a consistent willingness to fund ambitious, interdisciplinary approaches that sit at the frontier of discovery. Their support has extended beyond Oregon to institutions such as Stanford, OHSU, and other research centers, with a particular emphasis on diseases that carry both personal and societal urgency. In recent years, their philanthropy has increasingly focused on aging, cancer, and complex chronic conditions—areas where incremental advances have proven insufficient and where new frameworks are required.

The Knight Initiative at Stanford exemplifies that approach. Since its launch, it has seeded nearly 70 research projects across dozens of departments, fostering collaborations that cut across neuroscience, biology, engineering, and data science.

This cross-disciplinary structure has already generated a growing body of published research and attracted significant follow-on funding from federal agencies and other institutions. The new $90 million infusion is expected to expand that ecosystem by supporting additional investigators and enhancing the initiative’s core infrastructure, including its Brain Resilience Laboratory.

At the heart of the lab’s work is the creation of a comprehensive molecular atlas of the aging human brain, an effort that seeks to chart how gene expression, protein activity, and cellular metabolism evolve over time.

By assembling and analyzing tissue samples from multiple brain regions across the lifespan, researchers aim to establish a baseline understanding of what “healthy” brain aging looks like—an area that has historically been underexplored. The resulting datasets, which Stanford plans to make openly available, are intended to serve as a global resource for scientists pursuing new therapeutic strategies.

The initiative’s next phase will push further into experimental territory, including the development of living cellular models that allow researchers to test how specific biological pathways influence aging and how they might be altered.

In parallel, advanced AI systems will be deployed to detect subtle patterns within vast datasets, potentially identifying early indicators of resilience or vulnerability that could guide future interventions. Taken together, these efforts reflect a shift toward predictive and preventative neuroscience, rather than reactive treatment.

For the Knights, the investment also underscores a long-standing belief in the power of curiosity-driven research. Penny Knight has emphasized the importance of focusing not only on disease but also on the conditions that enable people to live longer, healthier lives with their cognitive abilities intact.

That perspective aligns with a broader philanthropic trend among ultra-high-net-worth donors, who are increasingly directing capital toward longevity science and age-related health challenges as demographic shifts place new pressures on healthcare systems worldwide.

Yet the Knights’ approach remains distinctive in its scale and structure. Rather than dispersing smaller grants across a wide array of causes, their giving has often concentrated substantial resources into singular initiatives with the potential to redefine entire fields. This strategy carries inherent risk, but it also creates the conditions for breakthroughs that incremental funding rarely achieves.

At Stanford, that ambition is already reshaping the scientific landscape. The Knight Initiative has helped build a community of researchers united not by discipline, but by a shared objective: understanding why some brains endure. Through regular symposia, collaborative grants, and open data sharing, the program has fostered an environment in which unconventional ideas can gain traction and insights from disparate fields can converge.

As the global population ages, the stakes of that work continue to rise. Neurodegenerative diseases remain among the most complex and costly health challenges, affecting millions of individuals and families while eluding effective long-term treatments. By investing in the underlying biology of resilience, the Knights are effectively betting that the answers may lie not only in combating disease, but in understanding—and ultimately replicating—the mechanisms that allow the brain to thrive despite it.

The latest $90 million gift ensures that this line of inquiry will continue to expand at a critical moment for the field. It also strengthens Penny and Phil Knight’s position as among the most influential philanthropists supporting scientific innovation, with a legacy focused on enabling discoveries that could extend both lifespan and health span. In doing so, their giving is helping to redefine what it means to age—and what it might one day mean to do so without decline.